Narix Pharmaceuticals Private Limited

Jyseleca (Filgotinib) Tablet Preferential JAK1 Inhibitor for RA & Ulcerative Colitis Narix Pharmaceuticals Narix Pharmaceuticals manufactures Filgotinib Tablets, a preferential JAK1 inhibitor approved for rheumatoid arthritis (EU) and ulcerative colitis � with a favorable JAK1 selectivity profile aiming to preserve JAK2-mediated hematopoietic function. Key Therapeutic Uses: � Moderate-to-severe rheumatoid arthritis � MTX-inadequate � Moderate-to-severe ulcerative colitis � induction and maintenance � JAK-naive patients transitioning from biologics Available Strengths: 100 mg 200 mg Product Highlights: � Preferential JAK1 selectivity � spares JAK2 hematopoiesis � Approved for both RA and UC � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #FilgotinibTablet #JyselecaGeneric #PreferentialJAK1 #RheumatoidArthritisTablet #UlcerativeColitisTablet #FilgotinibManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine